Mov Disord Vol 36, Suppl 1 Archives - Page 108 of 132 - MDS Abstracts

MDS Virtual Congress 2021
Risk factors for the onset of dyskinesia in patients with Parkinson’s disease exhibiting wearing-off phenomena: A 1-year observational study in Japan (J-FIRST)
T. Mishima, SW. Chiu, H. Saiki, T. Yamaguchi, Y. Shimo, T. Maeda, H. Watanabe, K. Kashihara, M. Nomoto, N. Hattori, Y. Tsuboi (Fukuoka, Japan)
Objective: To investigate the risk factors for the onset of dyskinesia in patients with Parkinson's disease (PD) exhibiting wearing-off phenomena. Background: Dyskinesia occurs during long-term…
MDS Virtual Congress 2021
Cognitive assessment of Parkinson’s Disease patients in a Northeast Brazilian population: Current Challenges
J. Bonfadini, D. Lima, A. Carneiro, J. Luna, A. Damasceno, P. Braga-Neto (Fortaleza, Brazil)
Objective: To evaluate the influence of education level in the Mini-Mental Status Examination (MMSE) score in Parkinson’s Disease (PD) patients in a northeast Brazilian sample.…
MDS Virtual Congress 2021
Reduced Alpha suppression & altered EEG signal complexity in Parkinson’s disease – signatures of cognitive impairment?
S M. Keller, A. Meyer, U. Gschwandtner, S M. Beltrani, K. Toloraia, P. Fuhr (Basel, Switzerland)
Objective: In a cross-sectional setting both alpha suppression and complexity of alpha-band oscillations are evaluated as diagnostic biomarker for assessing MCI in early stages of…
MDS Virtual Congress 2021
Falls in Parkinson’s Disease: The Impact of Cognitive Performance
F. Rolim, A. Gomes, V. Santos, D. Torres, F. Carvalho (Fortaleza, Brazil)
Objective: This study aimed to assess the incidence of falls in a population of PD patients and their clinical performance on cognitive assessment scales. Background:…
MDS Virtual Congress 2021
Parkinson’s-disease risk variants are differentially associated with discrete phenotypic characteristics of Parkinson’s-disease at baseline.
B. Chase, A. Premkumar, B. Schoneburg, N. Kartha, J. Wei, H. Yu, A. Epshteyn, L. Garduno, A. Pham, R. Vazquez, R. Frigerio, D. Maraganore, K. Markopoulou (Skokie, USA)
Objective: Evaluate whether genetic risk variants for Parkinson’s disease discovered in case-control GWAS uniformly or differentially contribute to the clinical phenotype of PD. Background: Genetic…
MDS Virtual Congress 2021
SHBG, and possibly testosterone, are associated with the risk for Parkinson’s disease among women: a Mendelian randomization approach
C. Kusters, K. Paul, A. Duarte Folle, A. Keener, J. Bronstein, L. Bertram, J. Hansen, S. Horvath, J. Sinsheimer, C. Lill, B. Ritz (Los Angeles, USA)
Objective: To assess the association between Sex Hormone Binding Globulin (SHBG), Testosterone, and Estradiol with Parkinson's disease (PD). Background: Sex hormones may protect dopaminergic neurons,…
MDS Virtual Congress 2021
Ultrastructural Characterization of Monocytes in Parkinson’s Disease and GBA mutations
GM. Riboldi, S. Dilipkumar, A. Sowa, A. Allen, K. Astudillo, J. Crary, S. Frucht, T. Raj, W. Janseen (New York, USA)
Objective: To identify morphological changes in circulating CD14+ monocytes in manifesting and non-manifesting carriers of mutations of the GBA gene and Parkinson’s disease (PD). Background: Mutations of…
MDS Virtual Congress 2021
The MJFF Global Genetic Parkinson’s Disease Research Resource
EJ. Vollstedt, JO. Aasly, B. Al Mubarak, R. Alcalay, V. Alvarez, I. Amorin, G. Annesi, D. Arkadir, M. Barkhuizen, D. Berg, V. Bonifati, A. Boon, L. Brighina, K. Brockmann, A. Carmine Belin, J. Carr, J. Clarimon, M. Cornejo-Olivas, JC. Corvol, D. Crosiers, J. Damasio, P. Das, P. Carvalho Aguiar, A. de Rosa, J. Dorszewska, S. Ertan, R. Ferese, J. Ferreira, E. Gatto, N. Giladi, H. Hanagasi, N. Hattori, F. Hentati, S. Illarioshkin, J. Jankovic, P. Klivenyi, V. Kostic, D. Koziorowski, A. Lang, SY. Lim, CH. Lin, K. Lohmann, M. Martikainen, G. Mellick, M. Merello, P. Mir, M. Pimentel, T. Pulkes, A. Puschmann, E. Sammler, M. Skaalum Petersen, M. Skorvanek, M. Spitz, L. Stefanis, O. Suchowersky, V. Tumas, EM. Valente, B. de Warrenburg, C. Williams-Gray, R. Wu, B. Zhang, A. Zimprich, C. Klein (Luebeck, Germany)
Objective: To establish a comprehensive research and clinical trial-ready resource of centers working with individuals with monogenic Parkinson’s Disease (PD). Background: As gene-targeted therapies are…
MDS Virtual Congress 2021
CHARACTERIZATION OF LRP10 EXPRESSION IN LEWY BODY DISORDERS AND IPSC-DERIVED BRAIN CELLS
M. Grochowska, A. Carreras Mascaro, V. Boumeester, D. Natale, G. Breedveld, H. Geut, W. van Cappellen, A. Boon, A. Kievit, E. Sammler, P. Parchi, P. Cortelli, D. Alessi, W. V.D. Berg, V. Bonifati, W. Mandemakers (Rotterdam, Netherlands)
Objective: Our objective is to characterize endogenous low-density lipoprotein-related protein 10 (LRP10) expression in human induced pluripotent stem cell (iPSC)-derived brain cell types, post-mortem brain…
MDS Virtual Congress 2021
The Role Imposed by The High-Mobility Group Box 1 (HMGB1) Protein in MPTP-Induced Zebrafish Model of Parkinson’s Disease
K. Razali, WMY. Mohamed, N. Othman, MHM. Nasir, AA. Doolanea, J. Kumar (Kuantan, Malaysia)
Objective: This study aims to investigate the role of HMGB1 protein in mediating neuroinflammatory-induced parkinsonian movement disorder of the MPTP-induced zebrafish model of Parkinson's disease…